Accelerate Diagnostics Inc Total Assets
Accelerate Diagnostics Inc total assets. Based on the latest financial reports, Accelerate Diagnostics Inc (AXDX) holds total assets worth $28.56 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AXDX market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Accelerate Diagnostics Inc (1996–2024)
Total assets of Accelerate Diagnostics Inc from 1996 to 2024. This chart illustrates how Accelerate Diagnostics Inc's total assets have evolved over time, based on quarterly financial data. See latest Accelerate Diagnostics Inc stock price today for real-time trading data and today's change.
Accelerate Diagnostics Inc - Asset Composition Analysis
Accelerate Diagnostics Inc Total Assets Breakdown (December 2024)
Accelerate Diagnostics Inc total assets breakdown as of December 2024. Accelerate Diagnostics Inc's total assets of $28.56 Million consist of 77.9% current assets and 22.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.9% |
| Accounts Receivable | $2.04 Million | 7.1% |
| Inventory | $2.85 Million | 10.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Accelerate Diagnostics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Accelerate Diagnostics Inc (AXDX) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Accelerate Diagnostics Inc's current assets represent 77.9% of total assets in 2024, a decrease from 87.0% in 1996.
- Cash Position: Cash and equivalents constituted 52.9% of total assets in 2024, down from 60.9% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is inventory at 10.0% of total assets.
Accelerate Diagnostics Inc Competitors by Total Assets
Key competitors of Accelerate Diagnostics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.59 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Accelerate Diagnostics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.71 | 1.50 | 10.13 |
| Quick Ratio | 0.62 | 1.29 | 9.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-8.96 Million | $8.00 Million | $92.39 Million |
Accelerate Diagnostics Inc - Advanced Valuation Insights
This section examines the relationship between Accelerate Diagnostics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -9.0% |
| Total Assets | $28.56 Million |
| Market Capitalization | $859.92K USD |
Valuation Analysis
Below Book Valuation: The market values Accelerate Diagnostics Inc's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Accelerate Diagnostics Inc's assets decreased by 9.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Accelerate Diagnostics Inc (1996–2024)
The table below shows the annual total assets of Accelerate Diagnostics Inc from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $28.56 Million | -8.96% |
| 2023-12-31 | $31.37 Million | -51.76% |
| 2022-12-31 | $65.02 Million | -21.71% |
| 2021-12-31 | $83.05 Million | -11.11% |
| 2020-12-31 | $93.42 Million | -30.50% |
| 2019-12-31 | $134.42 Million | -27.44% |
| 2018-12-31 | $185.26 Million | +46.19% |
| 2017-12-31 | $126.73 Million | +52.96% |
| 2016-12-31 | $82.85 Million | -40.53% |
| 2015-12-31 | $139.32 Million | +99.60% |
| 2014-12-31 | $69.80 Million | +60.72% |
| 2013-12-31 | $43.43 Million | +152.30% |
| 2012-12-31 | $17.21 Million | +174.79% |
| 2011-12-31 | $6.26 Million | -0.07% |
| 2010-12-31 | $6.27 Million | +19.83% |
| 2009-12-31 | $5.23 Million | -10.23% |
| 2008-12-31 | $5.83 Million | -5.06% |
| 2007-12-31 | $6.14 Million | -21.79% |
| 2006-12-31 | $7.85 Million | -28.70% |
| 2005-12-31 | $11.01 Million | -13.49% |
| 2004-12-31 | $12.72 Million | -7.43% |
| 2003-12-31 | $13.75 Million | -8.51% |
| 2002-12-31 | $15.02 Million | +40.00% |
| 2001-12-31 | $10.73 Million | -18.11% |
| 2000-12-31 | $13.11 Million | -6.87% |
| 1999-12-31 | $14.07 Million | +0.70% |
| 1998-12-31 | $13.97 Million | +42.60% |
| 1997-12-31 | $9.80 Million | +326.09% |
| 1996-12-31 | $2.30 Million | -- |
About Accelerate Diagnostics Inc
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-po… Read more